DK3411034T3 - Selektiv østrogenreceptornedbrydere og anvendelser deraf - Google Patents

Selektiv østrogenreceptornedbrydere og anvendelser deraf Download PDF

Info

Publication number
DK3411034T3
DK3411034T3 DK17748247.8T DK17748247T DK3411034T3 DK 3411034 T3 DK3411034 T3 DK 3411034T3 DK 17748247 T DK17748247 T DK 17748247T DK 3411034 T3 DK3411034 T3 DK 3411034T3
Authority
DK
Denmark
Prior art keywords
decompositors
selective estrogen
reception
estrogen reception
selective
Prior art date
Application number
DK17748247.8T
Other languages
English (en)
Inventor
Yaolin Wang
Xing Dai
Original Assignee
Inventisbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventisbio Inc filed Critical Inventisbio Inc
Application granted granted Critical
Publication of DK3411034T3 publication Critical patent/DK3411034T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK17748247.8T 2016-02-05 2017-02-03 Selektiv østrogenreceptornedbrydere og anvendelser deraf DK3411034T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291921P 2016-02-05 2016-02-05
PCT/US2017/016452 WO2017136688A1 (en) 2016-02-05 2017-02-03 Selective estrogen receptor degraders and uses thereof

Publications (1)

Publication Number Publication Date
DK3411034T3 true DK3411034T3 (da) 2021-01-11

Family

ID=59501091

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17748247.8T DK3411034T3 (da) 2016-02-05 2017-02-03 Selektiv østrogenreceptornedbrydere og anvendelser deraf

Country Status (15)

Country Link
US (4) US10647724B2 (da)
EP (1) EP3411034B1 (da)
JP (1) JP6905539B2 (da)
KR (1) KR102479822B1 (da)
CN (2) CN113004273A (da)
AU (1) AU2017213614B2 (da)
BR (1) BR112018015419B1 (da)
CA (1) CA3012078C (da)
DK (1) DK3411034T3 (da)
ES (1) ES2842579T3 (da)
IL (1) IL260789B (da)
MX (1) MX2018009496A (da)
RU (1) RU2734501C2 (da)
WO (1) WO2017136688A1 (da)
ZA (1) ZA201805573B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
KR102099159B1 (ko) * 2015-11-12 2020-04-10 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 아크릴산 유도체, 그의 제조방법 및 의약에 있어서의 그의 사용방법
US10647724B2 (en) * 2016-02-05 2020-05-12 Inventisbio Inc. Selective estrogen receptor degraders and uses thereof
CN108699514B (zh) * 2016-02-26 2023-07-07 隆萨沃克斯维尔股份有限公司 汇集肝细胞的方法
CN109311870B (zh) * 2016-04-01 2021-09-21 里科瑞尔姆Ip控股有限责任公司 雌激素受体调节剂
CN109311876B (zh) * 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
CN107814798B (zh) * 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
MX2020008906A (es) 2018-02-28 2021-02-26 Ferro Therapeutics Inc Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
CN111770924B (zh) * 2018-04-04 2023-05-09 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
CR20200621A (es) 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
MX2021001857A (es) 2018-08-17 2021-10-13 Genentech Inc Star Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama.
MX2021007687A (es) * 2018-12-24 2021-10-13 Inventisbio Co Ltd Sales novedosas de degradadores selectivos de receptores de estrogeno.
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
WO2020238733A1 (zh) * 2019-05-24 2020-12-03 浙江海正药业股份有限公司 丙烯酸类衍生物的晶型及其制备方法和用途
CN114269342A (zh) 2019-08-06 2022-04-01 里科瑞尔姆Ip控股有限责任公司 用于治疗突变的雌激素受体调节剂
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
WO2024042163A1 (en) * 2022-08-25 2024-02-29 Sanofi Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003205630A1 (en) 2002-01-18 2003-07-30 The Genetics Company Inc. Beta-secretase inhibitors
US20030225132A1 (en) * 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators
WO2004091488A2 (en) 2003-04-14 2004-10-28 Merck & Co., Inc. Estrogen receptor modulators
PT1737461E (pt) * 2004-03-15 2013-03-18 Ptc Therapeutics Inc Derivados de carbolina úteis na inibição de angiogénese
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
WO2010138685A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
RU2012120858A (ru) * 2009-10-22 2013-11-27 Полимедикс, Инк. Способы получения полимерного соединения
CA2800673A1 (en) * 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
TWI560172B (en) * 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
WO2013090829A1 (en) * 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US20140122109A1 (en) * 2012-10-29 2014-05-01 Consuli, Inc. Clinical diagnosis objects interaction
CN105121413B (zh) 2013-03-14 2018-09-14 赛拉根医药股份有限公司 多环雌激素受体调节剂及其用途
CA2911859A1 (en) 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds
KR20160021281A (ko) 2013-06-19 2016-02-24 세라곤 파마슈티컬스, 인크. 아제티딘 에스트로겐 수용체 조절제 및 이의 용도
CA2941161A1 (en) * 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
EP3156054A4 (en) 2014-06-12 2018-03-14 ONO Pharmaceutical Co., Ltd. Medicine for preventing and/or treating stress-induced diseases
TWI784255B (zh) * 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
AU2016279330B2 (en) 2015-06-16 2020-05-14 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
LT3355884T (lt) * 2015-10-01 2021-07-26 Olema Pharmaceuticals, Inc. Tetrahidro-1h-pirido[3,4-b]indolo antiestrogeniniai vaistai
KR102099159B1 (ko) 2015-11-12 2020-04-10 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 아크릴산 유도체, 그의 제조방법 및 의약에 있어서의 그의 사용방법
US10647724B2 (en) * 2016-02-05 2020-05-12 Inventisbio Inc. Selective estrogen receptor degraders and uses thereof
CN109311870B (zh) 2016-04-01 2021-09-21 里科瑞尔姆Ip控股有限责任公司 雌激素受体调节剂
WO2017216280A1 (en) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
CN109311876B (zh) 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
WO2018077260A1 (zh) 2016-10-28 2018-05-03 山东罗欣药业集团股份有限公司 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
WO2018130124A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
DK3494116T3 (da) 2017-01-30 2020-01-27 Astrazeneca Østrogenreceptormodulatorer
MX2021007687A (es) * 2018-12-24 2021-10-13 Inventisbio Co Ltd Sales novedosas de degradadores selectivos de receptores de estrogeno.

Also Published As

Publication number Publication date
CA3012078C (en) 2024-01-30
EP3411034A1 (en) 2018-12-12
US20200048250A1 (en) 2020-02-13
BR112018015419A2 (pt) 2018-12-18
AU2017213614B2 (en) 2022-09-01
JP6905539B2 (ja) 2021-07-21
AU2017213614A1 (en) 2018-08-09
WO2017136688A1 (en) 2017-08-10
US11014936B2 (en) 2021-05-25
US20200040001A1 (en) 2020-02-06
EP3411034B1 (en) 2020-11-25
KR102479822B1 (ko) 2022-12-21
CN109362222B (zh) 2021-03-19
CA3012078A1 (en) 2017-08-10
RU2018128318A3 (da) 2020-04-02
BR112018015419B1 (pt) 2024-01-30
RU2018128318A (ru) 2020-03-05
US20210253592A1 (en) 2021-08-19
ES2842579T3 (es) 2021-07-14
US20240043442A1 (en) 2024-02-08
CN113004273A (zh) 2021-06-22
KR20180104161A (ko) 2018-09-19
IL260789B (en) 2021-03-25
RU2734501C2 (ru) 2020-10-19
EP3411034A4 (en) 2019-08-28
US10647724B2 (en) 2020-05-12
JP2019504890A (ja) 2019-02-21
CN109362222A (zh) 2019-02-19
ZA201805573B (en) 2020-12-23
MX2018009496A (es) 2018-12-11

Similar Documents

Publication Publication Date Title
DK3411034T3 (da) Selektiv østrogenreceptornedbrydere og anvendelser deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3264955T3 (da) Blandeanordning og fremgangsmåde
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
DK3368534T3 (da) Valbenazin-ditosylat og polymorfer deraf
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3795177T3 (da) Claudin-18.2-specifikke immunoreceptorer og t-celleepitoper
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3127187T3 (da) Antenneanordning
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3658192T3 (da) Glucocorticoid-receptoragonist og immunokonjugater deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3113797T3 (da) Antistoffer, anvendelser og fremgangsmåder
DK3342571T3 (da) Blandeindretning og blandefremgangsmåde
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3054744T3 (da) Lederforbindelse og lederforbindelseskomponent
DK3442143T3 (da) Modtagelsesanordning og transmissionsanordning
DE102016117105A8 (de) Antenneneinrichtung
DK3265123T3 (da) Antistoffer, anvendelser og fremgangsmåder
DK3516160T3 (da) Brøndanordning og tilhørende fremgangsmåder
DE112017004251A5 (de) Antennenvorrichtung
DK3414420T3 (da) Brøndanordning og brøndsystem